Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Fibrocell Science initiated with a Buy at Rodman & Renshaw; tgt $2 (0.67)Rodman & Renshaw initiates FCSC with a Buy and price target of $2. Fibrocell has developed an expertise in fibroblasts and looks to target its assets to the treatment of disorders of the skin, connective tissue, and joints. A therapeutic goal is the targeting of monogenic diseases (single gene mutations), in order to «replace what is missing.» Driving the technology approaches is an ongoing partnership with Intrexon (<strong>XON</strong>), which is two separate deals including: 1) use of Intrexon's RheoSwitch Therapeutic System (RTS) for autoimmune and noninfectious inflammatory disorders; and 2) development programs for inflammatory and degenerative disorders of the joints. By leveraging Intrexon's expertise in synthetic biology and genetic engineering, Fibrocell will pay (based on agreement) Intrexon royalties and milestone payments on any approved programs to Intrexon.</td> </tr></table>"